Is 2.4mg Wegovy a strong dose — and what does it actually do?

You've been titrating for months and you're finally at 2.4mg, here's what that means

Picture the point most Wegovy users reach after roughly 16 weeks: the starter doses are behind them, the GI settling-in period has largely passed, and they are now injecting 2.4mg once a week. For a long time this was described, accurately, as the maintenance dose, the level the clinical trials were designed around and the dose most associated with the results that earned Wegovy its UK licence.

In the STEP 1 trial, adults taking semaglutide at 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks. The STEP 1 paper in the New England Journal of Medicine remains one of the most cited pieces of evidence for GLP-1 medicines in weight management, and 2.4mg is the dose those figures relate to. So in that evidence sense, yes, 2.4mg is a substantive, well-studied dose.

What it is not, however, is the absolute maximum. That changed in early 2026. The MHRA approved a 7.2mg maintenance dose, initially delivered as three 2.4mg pens per week, and then a dedicated single-dose 7.2mg pen in April 2026. So when people ask whether 2.4mg Wegovy is strong, the honest answer now has two parts: it is the dose with the deepest evidence base, and it remains the standard, but the licensed range has expanded. Your prescriber considers the full picture before deciding where you sit.

What the titration schedule tells us about why 2.4mg sits where it does

A common misconception is that the lower doses are just filler, that you're not really being treated until you hit 2.4mg. That's not quite right. Each rung of the schedule has a purpose. Starting at 0.25mg lets your digestive system adjust; moving through 0.5mg, 1mg and 1.7mg in roughly four-week steps means most people arrive at 2.4mg with far fewer side effects than if they'd begun there. The NHS semaglutide medicines page sets out the standard titration in plain terms and is worth reading alongside your patient information leaflet.

By the time you reach 2.4mg, the appetite-suppressing effect of semaglutide (working through GLP-1 receptors to slow gastric emptying and signal fullness) is generally well established. The drug accumulates over weeks; it does not switch on at 2.4mg. What changes is that at the maintenance dose, the pharmacological effect is at its intended level for the long term.

For a fuller look at how the doses stack up against each other, the Wegovy doses guide walks through each step and what the evidence says about each one. And if you are trying to understand whether an earlier point in the schedule is doing much, the page on whether 1mg Wegovy is strong covers that question directly.

Side effects at 2.4mg and what to watch for

Side effects at 2.4mg follow the same pattern as the rest of the schedule, just sometimes more pronounced, particularly if a dose increase was recent. Nausea, loose stools, constipation, indigestion and fatigue are the most reported. For most people they are manageable and ease within a couple of weeks of a dose change, which is part of why the titration schedule exists in the first place.

There are signs that warrant prompt medical attention rather than waiting. Severe stomach pain that spreads to the back (with or without vomiting) is not a normal side effect and could indicate pancreatitis. The MHRA highlighted acute pancreatitis as a known but serious risk in a January 2026 Drug Safety Update on GLP-1 medicines; if you experience that kind of pain, seek urgent medical help rather than managing it at home. Suspected side effects can also be reported directly at the MHRA Yellow Card scheme.

Gallbladder symptoms, signs of dehydration from persistent vomiting or diarrhoea, and any allergic reaction also need medical review. None of this makes 2.4mg a dangerous dose (it has an extensive safety record from large trials) but it is a prescription medicine for a reason, and having a prescriber to contact makes a real difference. For a broader overview of the Wegovy evidence and what the treatment involves, the Wegovy treatment overview is a good place to start.

Where 2.4mg fits now that 7.2mg exists, and what that means for you

The arrival of the 7.2mg dose in 2026 is worth putting in perspective. It is licensed specifically for adults with a BMI of 30 or above (the same population as standard Wegovy) but it is not a blanket next step for everyone who reaches 2.4mg. The MHRA's approval on 14 April 2026 was for a specific pen format, used once weekly, for people whose clinical profile makes the higher dose appropriate.

If you are currently at 2.4mg and wondering whether you should be on more, that is a conversation for your prescriber. They will look at your progress, how you have tolerated the current dose, and whether there is a clinical case for going further. The page on the strongest dose of Wegovy covers the 7.2mg development and what is known about it so far.

For context on cost, which often comes up alongside dosing questions, our Wegovy cost guide sets out what private treatment typically involves. And if you are still getting to grips with where 2.4mg sits relative to the doses just below it, the 1.7mg Wegovy page covers the penultimate step in detail.

If you want a prescriber to look at your situation specifically, speak to our prescribers through a free consultation, a real clinician reviews every case the same day.